BR0211067A - métodos e materiais para o tratamento de deficiência de testosterona em homens - Google Patents

métodos e materiais para o tratamento de deficiência de testosterona em homens

Info

Publication number
BR0211067A
BR0211067A BRPI0211067-9A BR0211067A BR0211067A BR 0211067 A BR0211067 A BR 0211067A BR 0211067 A BR0211067 A BR 0211067A BR 0211067 A BR0211067 A BR 0211067A
Authority
BR
Brazil
Prior art keywords
methods
men
treatment
materials
testosterone deficiency
Prior art date
Application number
BRPI0211067-9A
Other languages
English (en)
Inventor
Joseph Podolski
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23175972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0211067(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zonagen Inc filed Critical Zonagen Inc
Publication of BR0211067A publication Critical patent/BR0211067A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODOS E MATERIAIS PARA O TRATAMENTO DE DEFICIêNCIA DE TESTOSTERONA EM HOMENS". A presente invenção refere-se o uso de composições compreendendo trans-clomifeno para tratar homens com hipogonadismo. A invenção é também direcionada a métodos para tratar machos com hipogonadismo.
BRPI0211067-9A 2001-07-09 2002-07-09 métodos e materiais para o tratamento de deficiência de testosterona em homens BR0211067A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30431301P 2001-07-09 2001-07-09
PCT/US2002/021524 WO2003005954A2 (en) 2001-07-09 2002-07-09 Methods and materials for the treatment of testosterone deficiency in men

Publications (1)

Publication Number Publication Date
BR0211067A true BR0211067A (pt) 2006-10-31

Family

ID=23175972

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0211067-9A BR0211067A (pt) 2001-07-09 2002-07-09 métodos e materiais para o tratamento de deficiência de testosterona em homens

Country Status (24)

Country Link
US (6) US7759360B2 (pt)
EP (1) EP1411916B1 (pt)
JP (2) JP4845165B2 (pt)
KR (1) KR100851648B1 (pt)
CN (2) CN1289075C (pt)
AT (1) ATE406153T1 (pt)
AU (1) AU2002318225B2 (pt)
BR (1) BR0211067A (pt)
CA (2) CA2453337C (pt)
CL (1) CL2004000026A1 (pt)
CO (1) CO5550428A2 (pt)
CY (1) CY1108563T1 (pt)
DE (1) DE60228583D1 (pt)
DK (1) DK1411916T3 (pt)
EC (1) ECSP044937A (pt)
ES (1) ES2312593T3 (pt)
HK (1) HK1071521A1 (pt)
MX (1) MXPA04000097A (pt)
NZ (2) NZ551013A (pt)
PL (1) PL211339B1 (pt)
PT (1) PT1411916E (pt)
RU (1) RU2297218C2 (pt)
WO (1) WO2003005954A2 (pt)
ZA (1) ZA200400142B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406153T1 (de) 2001-07-09 2008-09-15 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
WO2006019916A1 (en) * 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
EP1848416A4 (en) * 2005-02-04 2008-09-24 Repros Therapeutics Inc METHOD AND MATERIALS USING TRANS-CLOMIPHES FOR TREATING MALE INACCURIBILITY
PL383444A1 (pl) * 2005-03-22 2008-03-17 Repros Therapeutics Inc. Sposoby dawkowania trans-klomifenu
US20080312239A1 (en) * 2007-06-13 2008-12-18 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US20110118355A1 (en) * 2007-09-21 2011-05-19 Harry Fisch Treatment of migraine headaches using antiestrogens
ME00996B (me) 2007-10-16 2012-10-20 Repros Therapeutics Inc Trans-klomifen za liječenje metaboličkog sindroma
WO2009052377A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
US20090215738A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
RU2474424C2 (ru) * 2010-09-24 2013-02-10 Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US20140235601A1 (en) * 2011-08-09 2014-08-21 Kenneth W. Adams Use of Aromatase Inhibitor Or Estrogen Blocker For Increasing Spermatogenesis Or Testosterone Levels In Males
IN2014DN10548A (pt) 2012-05-31 2015-08-21 Repros Therapeutics Inc
CN104582686A (zh) * 2012-08-21 2015-04-29 利普生物药剂公司 反式克罗米酚(trans-clomiphene)调配物和其用途
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
WO2014070523A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
US9814687B2 (en) * 2014-08-20 2017-11-14 Professional Compounding Centers Of America Transdermal pharmaceutical compositions including C-SERMs for low testosterone levels in men
RU2586305C1 (ru) * 2015-02-02 2016-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения обструктивной азооспермии и криптозооспермии у пациентов с хроническим простатитом
EP3368506B1 (en) 2016-04-22 2023-09-06 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3660489D1 (en) 1985-06-08 1988-09-15 Asta Pharma Ag Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) * 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
EP0802787A4 (en) 1994-06-17 1998-09-02 Univ Nebraska VECTOR FOR DELIVERY OF BIO-EFFECTIVE SUBSTANCES WITH GELLIFICATION -i (IN SITU) AND METHOD OF USE
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
DE69617245T2 (de) 1995-08-17 2002-07-25 Csir, Pretoria Produkte mit gesteuerter freisetzung
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ES2565163T3 (es) 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
ATE279461T1 (de) 1997-04-03 2004-10-15 Guilford Pharm Inc Bioabbaubare terephthalat polyester-polyphosphat polymere, zusammensetzungen, gegenstände und verfahren für ihre herstellung und verwendung
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
ATE355279T1 (de) 1998-08-07 2006-03-15 Novartis Vaccines & Diagnostic Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000076522A1 (en) 1999-06-11 2000-12-21 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CA2409647C (en) * 2000-05-26 2012-07-03 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
ES2228932T3 (es) 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040192598A1 (en) 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
ATE406153T1 (de) 2001-07-09 2008-09-15 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
JP2005507886A (ja) 2001-09-21 2005-03-24 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節剤としてのアンドロスタン類
US6600110B1 (en) * 2001-10-01 2003-07-29 Gram Precision Portable digital readout scale
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
JP4312522B2 (ja) 2003-06-30 2009-08-12 株式会社リコー 現像剤補給方法、現像剤補給装置、及び、画像形成装置
WO2006019916A1 (en) 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
EP1848416A4 (en) 2005-02-04 2008-09-24 Repros Therapeutics Inc METHOD AND MATERIALS USING TRANS-CLOMIPHES FOR TREATING MALE INACCURIBILITY
CA2597247A1 (en) 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
PL383444A1 (pl) 2005-03-22 2008-03-17 Repros Therapeutics Inc. Sposoby dawkowania trans-klomifenu
WO2007019165A1 (en) 2005-08-05 2007-02-15 Repros Therapeutics Inc. Methods and compositions for treating female infertility using clomiphene
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
ME00996B (me) 2007-10-16 2012-10-20 Repros Therapeutics Inc Trans-klomifen za liječenje metaboličkog sindroma
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TW201500041A (zh) 2008-11-07 2015-01-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
US20140235601A1 (en) 2011-08-09 2014-08-21 Kenneth W. Adams Use of Aromatase Inhibitor Or Estrogen Blocker For Increasing Spermatogenesis Or Testosterone Levels In Males

Also Published As

Publication number Publication date
CA2453337A1 (en) 2003-01-23
CY1108563T1 (el) 2014-04-09
US7368480B2 (en) 2008-05-06
US8618176B2 (en) 2013-12-31
MXPA04000097A (es) 2004-05-21
WO2003005954B1 (en) 2003-12-04
CO5550428A2 (es) 2005-08-31
CL2004000026A1 (es) 2005-02-04
US7759360B2 (en) 2010-07-20
KR20040013131A (ko) 2004-02-11
DE60228583D1 (de) 2008-10-09
CN1551765A (zh) 2004-12-01
DK1411916T3 (da) 2008-12-15
PL374121A1 (en) 2005-10-03
US20100286281A1 (en) 2010-11-11
US20150265553A1 (en) 2015-09-24
CA2453337C (en) 2012-08-28
RU2004100535A (ru) 2005-06-10
CN1289075C (zh) 2006-12-13
NZ530491A (en) 2007-08-31
NZ551013A (en) 2008-04-30
RU2297218C2 (ru) 2007-04-20
CN1954807A (zh) 2007-05-02
PL211339B1 (pl) 2012-05-31
WO2003005954A2 (en) 2003-01-23
ZA200400142B (en) 2006-02-22
JP2005520779A (ja) 2005-07-14
PT1411916E (pt) 2008-12-10
US20040097597A1 (en) 2004-05-20
JP4845165B2 (ja) 2011-12-28
CA2777199A1 (en) 2003-01-23
EP1411916A2 (en) 2004-04-28
WO2003005954A3 (en) 2003-10-23
ECSP044937A (es) 2004-04-28
EP1411916B1 (en) 2008-08-27
AU2002318225B2 (en) 2007-12-13
JP2009280623A (ja) 2009-12-03
ATE406153T1 (de) 2008-09-15
US20040241224A1 (en) 2004-12-02
ES2312593T3 (es) 2009-03-01
KR100851648B1 (ko) 2008-08-13
US20160354325A1 (en) 2016-12-08
US10561624B2 (en) 2020-02-18
EP1411916A4 (en) 2005-08-17
HK1071521A1 (en) 2005-07-22
US20140093560A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
BR0211067A (pt) métodos e materiais para o tratamento de deficiência de testosterona em homens
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
TW200501960A (en) Synergistic kits and compositions for treating cancer
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
DE60221234D1 (de) Verwendung von füllstoffe als sättigungsmittel
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
EP1262177A3 (en) Medical use of thyromimetic compounds to treat hair loss and compositions
DE60128673D1 (de) Verfahren zur verbesserung der grösse und des aussehens einer wunde
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
CA2418167A1 (en) Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
CA2408541A1 (en) Treating eczema and/or psoriasis
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
EP1546182A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSING AND TREATING TUMORS
BR0111785A (pt) Composições e métodos para tratamento de candidìase
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
PT1273296E (pt) Combinacao de acetildinalina e docetaxel
DE60136706D1 (de) Ycin-acryloyl derivate und antimetabolische mitteln

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]